Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Lenvima Plus Keytruda Associated With Better Results Than Sutent Alone in Patients With Advanced Type of Kidney Cancer

February 13th 2021

The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.

Novel Therapy Demonstrates Limited Activity and Poor Safety Outcomes in Patients With Metastatic Renal Cell Carcinoma

February 13th 2021

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.

Communication And Support Can Help Patients With Cancer Improve Their Quality of Life During Treatment

February 13th 2021

For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.

New Options for Renal Cell Carcinoma Could Offer Hope, But Sequencing and a Personalized Approach Are Critical

February 12th 2021

Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.

Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype

February 12th 2021

Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.

Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies

February 11th 2021

Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.

Starting Treatment With Lenvima at a Higher Dose Improves Quality of Life and Symptom Control in Type of Kidney Cancer

February 11th 2021

A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.

New Combination Could Prove Beneficial After Immunotherapy in Patients with Clear Cell RCC

February 11th 2021

The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.

FDA Approves Cabometyx-Opdivo For Metastatic RCC Treatment

January 22nd 2021

After a fast-track designation, the Food and Drug Administration approved the combination of Cabometyx and Opdivo in the firstline setting for patients with advanced or metastatic renal cell carcinoma.

Age May Not Impact Outcomes from Metastatic Renal Cell Carcinoma Treatment Despite Increased Toxicity in Older Patients

January 11th 2021

Patients older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival.

Phase 2 Study of Novel Drug and Cabometyx Combo in Advanced or Metastatic Kidney Cancer Fails to Meet its Main Goal of Improving Progression-Free Survival

January 5th 2021

Patients with advanced or metastatic kidney cancer treated with the novel drug combination achieved a median progression-free survival of 9.2 months compared to 9.3 months among patients who received Cabometyx with a placebo.

Kidney Cancer News and Updates That Patients May Have Missed in 2020

January 5th 2021

A roundup of some kidney cancer news and updates that occurred in 2020 that patients may have missed.

Deciding Whether to Receive the COVID-19 Vaccine — and Which One — As More Are Authorized for Emergency Use by the FDA

December 21st 2020

With the second COVID-19 vaccine receiving emergency use authorization by the FDA, patients with cancer undergoing treatment should keep in mind how it may affect their therapy and the potential difference between the two vaccines by Pfizer-BioNTech and Moderna.

Promising Drug Puts Focus on Rare Condition That Can Lead to Growth of Tumors, Cysts

November 5th 2020

The FDA is reviewing what could become the first-ever medication specifically for kidney cancer associated with von Hippel-Lindau disease.

Can a Blood Test Detect Cancer in Asymptomatic Patients?

October 28th 2020

A liquid biopsy may soon be available to find early signs of cancer in asymptomatic patients when the disease is still treatable and even curable.

FDA Grants Priority Review to Opdivo-Cabometyx Combo for Advanced Kidney Cancer

October 27th 2020

The FDA granted a priority review to the biologics license application and new drug application for the combination of Opdivo and Cabometyx for patients with advanced kidney cancer.

Cabometyx-Tecentriq Combo Shows Promise in Advanced Kidney Cancer

October 5th 2020

“The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” Dr. Sumanta Kumar Pal, co-director of the Kidney Cancer Program at City of Hope in California, said during a presentation of the clear cell renal cell carcinoma cohort.

Surgery After Targeted or Immune Therapy Improves Health Outcomes in Some Patients with Metastatic Kidney Cancer

October 1st 2020

For some patients with metastatic kidney cancer, undergoing surgery after targeted or immune therapy sparks better health outcomes.

Data Sharing, Vigilance Pivotal in Maintaining Patient Safety While Treating Cancer Amid the COVID-19 Pandemic

September 2nd 2020

As the COVID-19 pandemic continues to impact the care of patients with metastatic renal cell carcinoma and other cancers, health care professionals are working together to stay vigilant and make the best treatment decisions for their patients by pooling their data with tools like the COVID-19 and Cancer Consortium, says Dr. Toni K. Choueiri.

Age and Gender Could Factor into Advanced Renal Cell Carcinoma Outcomes

September 1st 2020

Many factors impact outcomes in patients with advanced renal cell carcinoma, but recent findings suggest a patient’s age and gender are perhaps more important than previously realized.

FDA Approves First Comprehensive Genomic Profiling Liquid Biopsy Test for All Solid Cancers

August 10th 2020

The liquid biopsy test was also approved as a companion diagnostic test to uncover EGFR mutations in patients with NSCLC who could benefit from treatment with Tagrisso.

An Expert Looks to the Future of Metastatic Kidney Cancer Treatment

August 10th 2020

Dr. Toni K. Choueiri discusses what therapies are currently available for patients with metastatic renal cell carcinoma, as well as what new treatments could be on the horizon.

FDA Grants Breakthrough Therapy Designation to Novel Therapy for von Hippel-Lindau Disease-Associated RCC

August 7th 2020

The FDA based its decision on data from a phase 2 trial which showed that MK-6482 induced clinical responses among patients with von Hippel-Lindau disease-associated kidney cancer.

Opdivo-Yervoy Combination Shows Promise in Certain Patients with Previously Treated RCC

August 6th 2020

While the combination of Opdivo and Yervoy is one of several treatment options for patients with metastatic renal cell carcinoma, many patients will likely progress after initial treatment. However, new research shows that when used after immune checkpoint inhibition, the combination shows promise.

Combination of Avastin and Tarceva 'Should Be Considered Preferred Option' in Kidney Cancer Subtype

July 10th 2020

Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and renal cell carcinoma or sporadic papillary renal cell carcinoma.

Experimental Therapy Demonstrates 'Encouraging Efficacy and Improved Safety' Over Standard-of-Care Treatment in Kidney Cancer Subset

July 10th 2020

Data from a phase 3 study presented at the 2020 ASCO Virtual Scientific Program showed that treatment with savolitinib demonstrated encouraging efficacy and an improved safety over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary renal cell carcinoma.

The Latest News and Updates in Kidney Cancer

July 8th 2020

A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.

More Options in Renal Cell Carcinoma Treatment Means Greater Hope For Patients

June 22nd 2020

A variety of novel treatments, including immunotherapies, extend life for patients with advanced kidney cancer.

Navigating Kidney Cancer Treatment During COVID-19

June 8th 2020

Getting kidney cancer treatment during the COVID-19 pandemic.

What Comes Next For Patients With Kidney Cancer

June 8th 2020

Kidney cancer positives that might come from this pandemic.